|
Targeting TP53 Mutations in Myelodysplastic Syndromes |
Apr 2020 |
Hematology/oncology clinics of North America |
Myelodysplastic Syndromes (MDS) |
|
Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities |
Mar 2020 |
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter? |
Mar 2020 |
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Clonal selection in therapy related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment |
Jan 2020 |
European Journal of Haematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria |
Jan 2020 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes |
Jan 2020 |
The New England Journal of Medicine |
Myelodysplastic Syndromes (MDS) |
|
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study |
Jan 2020 |
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
|
Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria |
Dec 2019 |
Leukemia & Lymphoma |
Aplastic Anemia |
|
Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party |
Dec 2019 |
Bone Marrow Transplantation |
Aplastic Anemia |
|
Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: A SEER-medicare analysis |
Dec 2019 |
Leukemia |
Myelodysplastic Syndromes (MDS) |
